Long-Term Efficacy of Mirabegron Add-On Therapy to Antimuscarinic Agents in Patients With Spinal Cord Injury

Ann Rehabil Med, 2019 · DOI: https://doi.org/10.5535/arm.2019.43.1.54 · Published: January 1, 2019

Simple Explanation

This study investigated the long-term effects of adding mirabegron to existing antimuscarinic treatments for bladder issues in people with spinal cord injuries. The study found that adding mirabegron improved bladder capacity, reflex volume, and bladder compliance, and reduced leakage. These findings suggest that mirabegron can be a helpful addition to standard treatments for bladder dysfunction in individuals with spinal cord injuries, improving their bladder function over the long term.

Study Duration

At least 6 months

Participants

31 individuals with spinal cord injury

Evidence Level

Not specified

Key Findings

1
A significant increase in cystometric capacity was observed (mean, 362 to 424 mL; p=0.03) after adding mirabegron to antimuscarinic therapy.
2
Reflex volume significantly increased (mean, 251 to 329 mL; p=0.02) with the addition of mirabegron.
3
Bladder compliance improved significantly (median, 12 to 18 mL/cmH2O; p=0.04) with the add-on therapy.

Research Summary

This study evaluated the long-term efficacy of mirabegron add-on therapy to antimuscarinic agents in patients with spinal cord injury (SCI) based on an urodynamic study. The results showed a significant increase in cystometric capacity, reflex volume, and bladder compliance, along with a significant reduction in leakage during filling cystometry. The study concluded that adding mirabegron to conventional antimuscarinics further improved urodynamic parameters in patients with chronic SCI, and sustained efficacy was observed in long-term use.

Practical Implications

Improved Bladder Management

Mirabegron add-on therapy can significantly improve bladder capacity and compliance in SCI patients.

Reduced Leakage

The study showed a reduction in urinary leakage, enhancing the quality of life for patients.